XOSPATA (gilteritinib) tablets is used to treat acute myeloid leukemia (AML).
Generic Name: Gilteritinib Tablets. Brand Name: XOSPATA Tablets.

What gilteritinib is and used for?

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. It was developed by Astellas Pharma. In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).

In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients. Gilteritinib was approved for medical use in Australia in March 2020.

Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

NEWS / UPDATES

• For Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details 
• FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation For More Details 
• FDA Approves Update to Gilteritinib AML Label to Include OS Data For More Details